N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide
- CAS No.
- 1798310-55-0
- Chemical Name:
- N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide
- Synonyms
- AR420626;AR420626, 10 mM in DMSO;AR420626,Inhibitor,inhibit;N-(2,5-Dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide;3-Quinolinecarboxamide, N-(2,5-dichlorophenyl)-4-(2-furanyl)-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-;N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide
- CBNumber:
- CB03544752
- Molecular Formula:
- C21H18Cl2N2O3
- Molecular Weight:
- 417.29
- MDL Number:
- MOL File:
- 1798310-55-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide Properties
| Boiling point | 619.3±55.0 °C(Predicted) |
|---|---|
| Density | 1.42±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMF: 2 mg/ml; DMSO: 5 mg/ml; DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml |
| form | A crystalline solid |
| pka | 12.30±0.70(Predicted) |
| color | Off-white to light yellow |
| InChI | 1S/C21H18Cl2N2O3/c1-11-18(21(27)25-15-10-12(22)7-8-13(15)23)20(17-6-3-9-28-17)19-14(24-11)4-2-5-16(19)26/h3,6-10,20,24H,2,4-5H2,1H3,(H,25,27) |
| InChIKey | GGTYQECCGLBHGS-UHFFFAOYSA-N |
| SMILES | ClC1=CC(NC(C2=C(C)NC(CCCC3=O)=C3C2C4=CC=CO4)=O)=C(Cl)C=C1 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P501 |
| WGK Germany | WGK 3 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral |
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide price More Price(39)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML1339 | AR420626 ≥98% (HPLC) | 1798310-55-0 | 5 mg | $126 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML1339 | AR420626 ≥98% (HPLC) | 1798310-55-0 | 25 mg | $509 | 2026-04-30 | Buy |
| Cayman Chemical | 17531 | AR-420626 ≥95% | 1798310-55-0 | 5mg | $61 | 2026-04-30 | Buy |
| Cayman Chemical | 17531 | AR-420626 ≥95% | 1798310-55-0 | 10mg | $116 | 2026-04-30 | Buy |
| Cayman Chemical | 17531 | AR-420626 ≥95% | 1798310-55-0 | 25mg | $273 | 2026-04-30 | Buy |
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide Chemical Properties,Uses,Production
Uses
AR 420626 is a selective and moderately potent positive allosteric modular (PAM)-agonist of the FFA3 receptor, which inhibits short chain fatty acids in a noncompetitive manner as a negative allosteric modulator in human and rodent cells.
Biological Activity
AR420626 is a selective agonist of Free Fatty Acid 3 receptor FFA3 (previously called GPR41). FFA3 is expressed in adipose tissue, gut, and the peripheral nervous system and normally activated by short chain fatty acids (SCFAs) produced in the body through the fermentation of complex carbohydrates by the gut microbiota. There is increasing interest in the role of the various free fatty acid receptors and SCFAs as chemical messengers in energy regulation and regulation of inflammatory processes and as therapeutic targets in the treatment of various metabolic and inflammatory conditions. AR420626 has an EC50 value of 117 nM for FFAR3 and did not activate FFAR2 in concentrations up to 100 μM.
in vivo
AR420626 (0.1 mg/kg, i.p.; single dose) inhibits serotonin-induced defecation volume in male Sprague-Dawley rats[1]. AR420626 (0.1 mg/kg, i.p.; days 0-4; 0.2 mg/kg, i.p.; days 7-11) inhibits the growth of HepG2 xenografted male SHO nude mice[2]. AR420626 (0.1 mg/kg, i.p.; administered 30 minutes before modeling) inhibits the immune response in bronchoalveolar lavage fluid (BALF) and lung tissue of the allergic asthma model induced by ovalbumins (HY-W250978) in BALB/c mice; and inhibits the skin inflammatory immune response, cervical lymph node immune response and the development of eczema symptoms in the eczema model induced by 1-chloro-2, 4-dinitrobenzene (DNCB) in BALB/c mice[3]. AR420626 (13.32 and 26.64 μg/kg, i.p.; once a day for 7 days) at a dose of 26.64 μg/kg improves glucose tolerance by increasing plasma insulin levels and skeletal muscle glycogen content in male ICR mice with Streptozotocin (HY-13753) induced diabetes and C57BL/6 mice with high-fat diet-induced diabetes[4].
| Animal Model: | HepG2 xenograft model in male SHO nude mice [2] |
| Dosage: | 0.1 mg/kg on days 0-4 after tumors reach 500-1000 mm3 0.2 mg/kg on days 7-11 after tumors reach 500-1000 mm3 |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited the growth of HepG2 xenograft mice, and still had an inhibitory effect on the weight of mice after stopping administration. |
| Animal Model: | Ovalbumin (OVA)-induced asthma induction in BALB/c mice [3] |
| Dosage: | 0.1 mg/kg |
| Administration: | Intraperitoneal injection 30 min before OVA sensitization (D0 and D14) or 30 min before OVA challenge (D28, D29, and D30) |
| Result: | Suppressed the increased IL-4 and IL-17A levels. Suppressed the increase in the number of eosinophils and total immune cells in bronchoalveolar lavage fluid (BALF). Inhibited the increase of cytokine (IL-4, IL-13, IFN-γ and IL-17a) levels. |
| Animal Model: | 1-chloro-2, 4-dinitrobenzene (DNCB)-induced eczema model in BALB/c mice[3] |
| Dosage: | 0.1 mg/kg |
| Administration: | Intraperitoneal injection 30 min before the DNCB challenge from day 19 |
| Result: | Reduced the number of accumulated immune cells and mast cells, inhibited acanthosis and epidermal thickening and mast cell accumulation, and inhibited IL-17A, TSLP and IL-8 levels. Inhibited immune responses in the cervical lymph nodes, size enlargement, and expression of inflammatory cytokines and chemokines, but did not enhance the proportion of CD4+FoxP3+ Treg cells. |
storage
Store at -20°C
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide Preparation Products And Raw materials
Raw materials
Preparation Products
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Nanjing Chemlin Chemical Co., Ltd | 025-83697070 13770331960 | info@chemlin.com.cn | China | 16305 | 64 |
| Shanghai Raise Chemical Technology Co.,Ltd | 15026594951 | rs@raise-chem.com | China | 4905 | 55 |
| Shanghai Beckham Medical Technology Co., Ltd | 13816613772 | huahero21@sina.com | China | 2996 | 55 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9799 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Tianjin Kailiqi Biotechnology Co., Ltd. | 15076683720 | klq@cw-bio.com | China | 9796 | 55 |
| MQ (shanghai) Pharmaceuticals Co., Ltd. | 13761635123 | sales@linyuepharm.com | China | 5731 | 55 |
| Shanghai Hongye Biotechnology Co. Ltd | 400-9205774 400-920-5774 | sales@glpbio.cn | China | 6705 | 58 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
View Lastest Price from N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide manufacturers
N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide Spectrum
1798310-55-0(N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxamide)Related Search:
1of2
